ALCON INC
- Tickers
- ALC
- Headquarters
- Not recorded
- SEC CIK
- 0001167379
- Website
- Not recorded
Closing prices
Latest close, 71.83
| Date | Close |
|---|---|
| 78.61 | |
| 77.65 | |
| 76.61 | |
| 75.78 | |
| 75.42 | |
| 75.05 | |
| 76.61 | |
| 76.25 | |
| 79.66 | |
| 79.17 | |
| 79.31 | |
| 78.20 | |
| 79.20 | |
| 80.03 | |
| 78.99 | |
| 80.73 | |
| 78.87 | |
| 78.67 | |
| 80.21 | |
| 78.76 | |
| 78.80 | |
| 79.19 | |
| 79.02 | |
| 79.26 | |
| 79.50 | |
| 79.97 | |
| 80.55 | |
| 80.12 | |
| 80.17 | |
| 80.38 | |
| 80.35 | |
| 79.31 | |
| 78.81 | |
| 77.60 | |
| 80.65 | |
| 81.81 | |
| 81.02 | |
| 80.62 | |
| 80.13 | |
| 80.86 | |
| 78.99 | |
| 80.11 | |
| 79.67 | |
| 79.00 | |
| 79.06 | |
| 81.62 | |
| 81.02 | |
| 80.29 | |
| 80.79 | |
| 80.87 | |
| 80.42 | |
| 81.15 | |
| 80.98 | |
| 79.38 | |
| 77.33 | |
| 79.06 | |
| 78.37 | |
| 78.83 | |
| 78.44 | |
| 80.48 | |
| 79.39 | |
| 78.55 | |
| 79.20 | |
| 80.72 | |
| 82.29 | |
| 83.22 | |
| 82.63 | |
| 82.85 | |
| 84.13 | |
| 86.27 | |
| 86.72 | |
| 87.18 | |
| 84.68 | |
| 83.08 | |
| 84.27 | |
| 82.52 | |
| 81.33 | |
| 81.85 | |
| 80.65 | |
| 80.77 | |
| 78.50 | |
| 77.32 | |
| 77.79 | |
| 77.78 | |
| 75.74 | |
| 75.01 | |
| 73.65 | |
| 74.14 | |
| 74.24 | |
| 75.26 | |
| 74.47 | |
| 73.34 | |
| 73.67 | |
| 75.35 | |
| 75.51 | |
| 74.56 | |
| 74.63 | |
| 74.67 | |
| 77.31 | |
| 77.40 | |
| 78.01 | |
| 79.74 | |
| 79.94 | |
| 80.73 | |
| 79.55 | |
| 81.32 | |
| 80.30 | |
| 77.82 | |
| 76.43 | |
| 75.86 | |
| 75.80 | |
| 76.01 | |
| 75.40 | |
| 72.81 | |
| 74.87 | |
| 74.09 | |
| 73.48 | |
| 74.45 | |
| 65.41 | |
| 63.88 | |
| 62.56 | |
| 62.02 | |
| 63.78 | |
| 63.44 | |
| 64.00 | |
| 63.64 | |
| 65.97 | |
| 66.28 | |
| 67.28 | |
| 67.93 | |
| 67.78 | |
| 67.70 | |
| 66.35 | |
| 65.66 | |
| 66.29 | |
| 65.70 | |
| 64.28 | |
| 64.22 | |
| 66.58 | |
| 66.81 | |
| 66.11 | |
| 67.90 | |
| 66.11 | |
| 66.51 | |
| 66.85 | |
| 66.29 | |
| 65.84 | |
| 64.14 | |
| 64.68 | |
| 65.18 | |
| 66.12 | |
| 67.93 | |
| 68.13 | |
| 67.80 | |
| 67.61 | |
| 67.10 | |
| 66.82 | |
| 69.66 | |
| 68.33 | |
| 66.87 | |
| 66.56 | |
| 67.14 | |
| 67.81 | |
| 69.00 | |
| 66.86 | |
| 68.50 | |
| 70.62 | |
| 70.26 | |
| 70.04 | |
| 67.35 | |
| 67.35 | |
| 67.21 | |
| 67.91 | |
| 67.28 | |
| 69.11 | |
| 69.65 | |
| 69.61 | |
| 68.94 | |
| 70.21 | |
| 70.99 | |
| 70.57 | |
| 69.54 | |
| 71.81 | |
| 73.63 | |
| 75.35 | |
| 73.58 | |
| 73.52 | |
| 74.25 | |
| 72.49 | |
| 73.55 | |
| 74.26 | |
| 72.93 | |
| 73.63 | |
| 73.70 | |
| 73.37 | |
| 72.67 | |
| 72.23 | |
| 72.01 | |
| 72.06 | |
| 71.75 | |
| 72.24 | |
| 72.08 | |
| 70.50 | |
| 69.12 | |
| 68.43 | |
| 66.55 | |
| 66.03 | |
| 67.74 | |
| 67.76 | |
| 66.30 | |
| 65.18 | |
| 65.04 | |
| 64.87 | |
| 65.59 | |
| 65.39 | |
| 64.56 | |
| 64.47 | |
| 65.26 | |
| 65.44 | |
| 64.75 | |
| 63.94 | |
| 63.76 | |
| 64.33 | |
| 63.19 | |
| 63.00 | |
| 63.13 | |
| 64.11 | |
| 64.35 | |
| 63.00 | |
| 63.87 | |
| 66.58 | |
| 66.18 | |
| 66.13 | |
| 67.83 | |
| 67.43 | |
| 70.63 | |
| 70.17 | |
| 69.99 | |
| 69.42 | |
| 69.83 | |
| 71.13 | |
| 71.45 | |
| 73.63 | |
| 72.37 | |
| 77.31 | |
| 76.55 | |
| 74.94 | |
| 75.14 | |
| 74.06 | |
| 72.46 | |
| 71.83 |
Drugs
| Drug | Indications | Phase | Next catalyst | CT-VCA | Trials |
|---|---|---|---|---|---|
| Acoltremon | Not recorded | Approved | None scheduled | 0 | |
| Netarsudil | Ocular Hypertension; Open Angle Glaucoma | Approved | None scheduled | 1 |
FDA-approved applications
| Application | Brand names | Active ingredients | First approved | Status |
|---|---|---|---|---|
| NDA 220341 | BRYTLY | APRACLONIDINE HYDROCHLORIDE | Over-the-counter | |
| NDA 217370 | TRYPTYR | ACOLTREMON | Prescription | |
| NDA 210933 | EYSUVIS | LOTEPREDNOL ETABONATE | Prescription | |
| NDA 208259 | ROCKLATAN | LATANOPROST; NETARSUDIL DIMESYLATE | Prescription | |
| NDA 210565 | INVELTYS | LOTEPREDNOL ETABONATE | Discontinued | |
| NDA 208254 | RHOPRESSA | NETARSUDIL MESYLATE | Prescription | |
| NDA 208151 | ISOPTO ATROPINE | ATROPINE SULFATE | Prescription | |
| NDA 208135 | TETRACAINE HYDROCHLORIDE | TETRACAINE HYDROCHLORIDE | Prescription | |
| NDA 206276 | PATADAY ONCE DAILY RELIEF | OLOPATADINE HYDROCHLORIDE | Over-the-counter | |
| NDA 207926 | PHENYLEPHRINE HYDROCHLORIDE | PHENYLEPHRINE HYDROCHLORIDE | Prescription |
See all applications for ALCON INC
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 10,401,000,000 USD | 1 Jan 2025 to 31 Dec 2025 FY2025 | 20-F for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | 980,000,000 USD | 1 Jan 2025 to 31 Dec 2025 FY2025 | 20-F for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 990,000,000 USD | 1 Jan 2025 to 31 Dec 2025 FY2025 | 20-F for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | Not reported in XBRL filings since 2015 | ||
| Cash and cash equivalents | 1,527,000,000 USD | At 31 Dec 2025 FY2025 | 20-F for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | 0 USD | At 31 Dec 2022 FY2022 | 20-F for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed |
| Total liabilities | 9,520,000,000 USD | At 31 Dec 2025 FY2025 | 20-F for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | 22,035,000,000 USD | At 31 Dec 2025 FY2025 | 20-F for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 487,427,920 shares | At 31 Dec 2025 FY2025 | 20-F for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Jan 2025 to 31 Dec 2025 FY2025 | 10,401,000,000 USD | 20-F filed 24 Feb 2026 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2025 to 30 Jun 2025 FY2025 Q2 | 2,596,000,000 USD | 6-K filed 19 Aug 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2024 to 31 Dec 2024 FY2025 | 9,911,000,000 USD | 20-F filed 24 Feb 2026 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2024 to 30 Jun 2024 FY2025 Q2 | 2,496,000,000 USD | 6-K filed 19 Aug 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2023 to 31 Dec 2023 FY2025 | 9,455,000,000 USD | 20-F filed 24 Feb 2026 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2023 to 30 Jun 2023 FY2024 Q2 | 2,422,000,000 USD | 6-K filed 20 Aug 2024 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2022 to 31 Dec 2022 FY2024 | 8,717,000,000 USD | 20-F filed 25 Feb 2025 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2022 to 30 Jun 2022 FY2023 Q2 | 2,217,000,000 USD | 6-K filed 15 Aug 2023 on sec.gov (opens in a new tab)Filed |
The newest 12 periods of each metric are listed; older ones are on sec.gov.
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-11-11 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
Insider transactions
All rows for ALCON INC on Insider TradesLast 90 days of Form 4 filings, from 15 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction: none stored
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.